Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Total Liabilities
kr7.7B
CAGR 3-Years
51%
CAGR 5-Years
62%
CAGR 10-Years
23%
Zealand Pharma A/S
CSE:ZEAL
Total Liabilities
kr746.7m
CAGR 3-Years
16%
CAGR 5-Years
20%
CAGR 10-Years
33%
Ascendis Pharma A/S
NASDAQ:ASND
Total Liabilities
€1.1B
CAGR 3-Years
87%
CAGR 5-Years
64%
CAGR 10-Years
52%
B
Bavarian Nordic A/S
CSE:BAVA
Total Liabilities
kr3.8B
CAGR 3-Years
-3%
CAGR 5-Years
41%
CAGR 10-Years
28%
F
Fluoguide AS
STO:FLUO
Total Liabilities
kr16.9m
CAGR 3-Years
11%
CAGR 5-Years
201%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Total Liabilities
kr26.7m
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
11%
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Total Liabilities?
Total Liabilities
7.7B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Total Liabilities amounts to 7.7B DKK.

What is Genmab A/S's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
23%

Over the last year, the Total Liabilities growth was 137%. The average annual Total Liabilities growth rates for Genmab A/S have been 51% over the past three years , 62% over the past five years , and 23% over the past ten years .

Back to Top